DESTINY-Breast03 Phase 3 Study Results
DESTINY-Breast04 Summary and Impact
DESTINY-Breast04
Daiichi-Sankyo
T-DXd treatment showed unprecedented improvement in efficacy for patients with HER2-low mBC
Current mBC paradigm1,2
HER2+
HER2+
IHC 3+, 2+/ISH+
15%-20%
HER2-
HR+/HER2-
IHC 0, 1+, 2+/ISH-
-65%
HER2+
IHC 3+
IHC2+/ISH+
•
HER2-low:
IHC 1+ or
IHC 2+/ISH-
HER2-low
IHC 1+
IHC2+/ISH-
-50%
·
The new mBC paradigm
T-DXd is the first HER2-targeted
therapy to demonstrate improved
efficacy in HER2-low mBC
DESTINY-Breast04 establishes
T-DXd as the new standard of
care for HER2-low mBC
HR-/HER2-
(TNBC)
-15%
HER2-
IHC <1
Potential improvement for ~50%
of all mBC patients
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; T-DXd, trastuzumab deruxtecan; TNBC, triple-negative breast cancer; TPC, treatment of
physician's choice.
1. Schettini F, et al. NPJ Breast Cancer. 2021;7(1):1. 2. Tarantino P, et al. J Clin Oncol. 2020;38(17): 1951-1962.
ASCO 2022 #LBA3 Plenary Session
4View entire presentation